Lenvatinib resistance mechanism and potential ways to conquer
Lenvatinib (LVN) has been appoved to treat advanced renal cell carcinoma, differentiated thyroid carcinoma, hepatocellular carcinoma. Further other cancer types also have been tried in pre-clinic and clinic without approvation by FDA. The extensive use of lenvastinib in clinical practice is sufficie...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1153991/full |
| _version_ | 1797843648241467392 |
|---|---|
| author | Wentao Bo Yan Chen |
| author_facet | Wentao Bo Yan Chen |
| author_sort | Wentao Bo |
| collection | DOAJ |
| description | Lenvatinib (LVN) has been appoved to treat advanced renal cell carcinoma, differentiated thyroid carcinoma, hepatocellular carcinoma. Further other cancer types also have been tried in pre-clinic and clinic without approvation by FDA. The extensive use of lenvastinib in clinical practice is sufficient to illustrate its important therapeutic role. Although the drug resistance has not arised largely in clinical, the studies focusing on the resistance of LVN increasingly. In order to keep up with the latest progress of resistance caused by LVN, we summerized the latest studies from identify published reports. In this review, we found the latest report about resistance caused by lenvatinib, which were contained the hotspot mechanism such as the epithelial-mesenchymal transition, ferroptosis, RNA modification and so on. The potential ways to conquer the resistance of LVN were embraced by nanotechnology, CRISPR technology and traditional combined strategy. The latest literature review of LVN caused resistance would bring some ways for further study of LVN. We call for more attention to the pharmacological parameters of LVN in clinic, which was rarely and would supply key elements for drug itself in human beings and help to find the resistance target or idea for further study. |
| first_indexed | 2024-04-09T17:08:42Z |
| format | Article |
| id | doaj.art-82b2c9e426c94f66a339b7227fb29809 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-09T17:08:42Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-82b2c9e426c94f66a339b7227fb298092023-04-20T08:55:16ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-04-011410.3389/fphar.2023.11539911153991Lenvatinib resistance mechanism and potential ways to conquerWentao Bo0Yan Chen1Department of Hepatopancreatobiliary Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaLenvatinib (LVN) has been appoved to treat advanced renal cell carcinoma, differentiated thyroid carcinoma, hepatocellular carcinoma. Further other cancer types also have been tried in pre-clinic and clinic without approvation by FDA. The extensive use of lenvastinib in clinical practice is sufficient to illustrate its important therapeutic role. Although the drug resistance has not arised largely in clinical, the studies focusing on the resistance of LVN increasingly. In order to keep up with the latest progress of resistance caused by LVN, we summerized the latest studies from identify published reports. In this review, we found the latest report about resistance caused by lenvatinib, which were contained the hotspot mechanism such as the epithelial-mesenchymal transition, ferroptosis, RNA modification and so on. The potential ways to conquer the resistance of LVN were embraced by nanotechnology, CRISPR technology and traditional combined strategy. The latest literature review of LVN caused resistance would bring some ways for further study of LVN. We call for more attention to the pharmacological parameters of LVN in clinic, which was rarely and would supply key elements for drug itself in human beings and help to find the resistance target or idea for further study.https://www.frontiersin.org/articles/10.3389/fphar.2023.1153991/fullLenvatinibdrug resistancemechanismpharmacological parametershepatocellular carcinoma |
| spellingShingle | Wentao Bo Yan Chen Lenvatinib resistance mechanism and potential ways to conquer Frontiers in Pharmacology Lenvatinib drug resistance mechanism pharmacological parameters hepatocellular carcinoma |
| title | Lenvatinib resistance mechanism and potential ways to conquer |
| title_full | Lenvatinib resistance mechanism and potential ways to conquer |
| title_fullStr | Lenvatinib resistance mechanism and potential ways to conquer |
| title_full_unstemmed | Lenvatinib resistance mechanism and potential ways to conquer |
| title_short | Lenvatinib resistance mechanism and potential ways to conquer |
| title_sort | lenvatinib resistance mechanism and potential ways to conquer |
| topic | Lenvatinib drug resistance mechanism pharmacological parameters hepatocellular carcinoma |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1153991/full |
| work_keys_str_mv | AT wentaobo lenvatinibresistancemechanismandpotentialwaystoconquer AT yanchen lenvatinibresistancemechanismandpotentialwaystoconquer |